Zobrazeno 1 - 10
of 215
pro vyhledávání: '"J. Sande"'
Autor:
John Mukisa, Marion Amujal, Obondo J. Sande, Moses L. Joloba, Daudi Jjingo, David P. Kateete, Graeme Mardon, Mogomotsi Matshaba, Neil Hanchard, Jill A. Hollenbach
Publikováno v:
Translational Medicine Communications. 8
Host response to the human immune deficiency virus (HIV) involves both the innate and adaptive immune systems. As part of the innate immune system, the killer cell immunoglobulin-like receptors (KIRs) found on natural killer cells and some T-lymphocy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4d159f27551ac96ceb9d38d9fc6bf37
https://doi.org/10.1186/s41231-023-00141-z
https://doi.org/10.1186/s41231-023-00141-z
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Paul Katongole, Obondo J. Sande, Steven J. Reynolds, Moses Joloba, Henry Kajumbula, Samuel Kalungi, Kenneth Ssebambulidde, Cynthia Nakimuli, Maxine Atuheirwe, Jackson Orem, Nixon Niyonzima
Publikováno v:
Oncology and Therapy. 10:185-193
Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD-1/PD-L1 in prostate cancer,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aced0d531398b5cd0390138fdb0ed6eb
https://doi.org/10.1007/s40487-022-00184-6
https://doi.org/10.1007/s40487-022-00184-6
Autor:
Alex Kayongo, Nicole M. Robertson, Trishul Siddharthan, Moses Levi Ntayi, Josephine Caren Ndawula, Obondo J. Sande, Bernard S. Bagaya, Bruce Kirenga, Harriet Mayanja-Kizza, Moses L. Joloba, Sofia K. Forslund
Publikováno v:
Frontiers in Immunology. 13
Chronic Obstructive Pulmonary Disease (COPD) has significantly contributed to global mortality, with three million deaths reported annually. This impact is expected to increase over the next 40 years, with approximately 5 million people predicted to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9a166d058c5ed2b36a1dadfdd933e74
https://doi.org/10.3389/fimmu.2022.1085551
https://doi.org/10.3389/fimmu.2022.1085551
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Charles J Sande
Publikováno v:
The Lancet. Healthy longevity. 3(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a0b8c51675898cb012c50f5d0ecf8c
https://pubmed.ncbi.nlm.nih.gov/36098312
https://pubmed.ncbi.nlm.nih.gov/36098312
Autor:
Paul Katongole, Obondo J Sande, Sheilla Nabweyambo, Moses Joloba, Henry Kajumbula, Samuel Kalungi, Steven J Reynolds, Kenneth Ssebambulidde, Maxine Atuheirwe, Jackson Orem, Nixon Niyonzima
Publikováno v:
Future oncology (London, England). 18(6)
Background: The possible clinical application of specific cytokines and chemokines contributing to tumorigenesis and the clinical outcome of several cancers has been reported. However, less invasive and easily applicable biomarkers in prostate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044803ad746384747056ae8013ae2043
https://pubmed.ncbi.nlm.nih.gov/34881637
https://pubmed.ncbi.nlm.nih.gov/34881637
Autor:
Cynthia Nakimuli, Henry Kajumbula, Maxine Atuheirwe, Paul Katongole, Nixon Niyonzima, Obondo J. Sande, Jackson Orem, Samuel Kalungi, Kenneth Ssebambulidde, Moses M. Joloba, Steven J. Reynolds
Background The programmed death 1 (PD1)/programmed death-ligand 1 (PDL1) targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD1/PDL1 in prosta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ed5f438f42ccbdaee9f0563b8d29603
https://doi.org/10.21203/rs.3.rs-1107782/v1
https://doi.org/10.21203/rs.3.rs-1107782/v1
Autor:
M. C. Liefaard, A. van der Voort, M. van Seijen, B. Thijssen, J. Sanders, S. Vonk, L. Mittempergher, R. Bhaskaran, L. de Munck, A. E. van Leeuwen-Stok, R. Salgado, H. M. Horlings, E. H. Lips, G. S. Sonke
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab. However, it remains unclear if TILs could be a prognostic and/or predicti
Externí odkaz:
https://doaj.org/article/dfc1b1ee02aa46cab23090ed7177554b